AR118980A1 - Moléculas de unión a tigit y pd-1 / tigit - Google Patents

Moléculas de unión a tigit y pd-1 / tigit

Info

Publication number
AR118980A1
AR118980A1 ARP200101441A ARP200101441A AR118980A1 AR 118980 A1 AR118980 A1 AR 118980A1 AR P200101441 A ARP200101441 A AR P200101441A AR P200101441 A ARP200101441 A AR P200101441A AR 118980 A1 AR118980 A1 AR 118980A1
Authority
AR
Argentina
Prior art keywords
tigit
binding molecules
chemotherapy
human
binding polypeptide
Prior art date
Application number
ARP200101441A
Other languages
English (en)
Inventor
Yiqing Feng
Naresh Kumar
James David Pancook
Stephanie Marie Truhlar
Yang Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR118980A1 publication Critical patent/AR118980A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a las moléculas de polipéptidos que se unen a TIGIT humano, y a las moléculas de polipéptidos que se unen a PD-1 humano y a TIGIT humano, y son útiles para tratar tumores sólidos, solas y en combinación con quimioterapia y/o radiación ionizante.
ARP200101441A 2019-05-29 2020-05-21 Moléculas de unión a tigit y pd-1 / tigit AR118980A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853816P 2019-05-29 2019-05-29

Publications (1)

Publication Number Publication Date
AR118980A1 true AR118980A1 (es) 2021-11-17

Family

ID=71070067

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101441A AR118980A1 (es) 2019-05-29 2020-05-21 Moléculas de unión a tigit y pd-1 / tigit

Country Status (23)

Country Link
US (1) US20220227860A1 (es)
EP (1) EP3976652A1 (es)
JP (2) JP7241207B2 (es)
KR (1) KR20220004120A (es)
CN (1) CN113939536B (es)
AR (1) AR118980A1 (es)
AU (1) AU2020283817A1 (es)
BR (1) BR112021021795A2 (es)
CA (1) CA3139025A1 (es)
CL (1) CL2021003039A1 (es)
CO (1) CO2021015610A2 (es)
CR (1) CR20210573A (es)
DO (1) DOP2021000241A (es)
EA (1) EA202192796A1 (es)
EC (1) ECSP21085693A (es)
IL (1) IL287765A (es)
JO (1) JOP20210314A1 (es)
MA (1) MA56029A (es)
MX (1) MX2021014472A (es)
PE (1) PE20220505A1 (es)
SG (1) SG11202112725XA (es)
TW (1) TWI760751B (es)
WO (1) WO2020242919A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3565828T1 (sl) 2017-01-05 2022-04-29 Kahr Medical Ltd. SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
TW202327610A (zh) * 2021-08-30 2023-07-16 美商G1治療公司 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
TW202337897A (zh) * 2021-11-18 2023-10-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
TW202409083A (zh) 2022-05-02 2024-03-01 美商阿克思生物科學有限公司 抗-tigit抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3021869T (pt) * 2013-07-16 2020-09-10 Hoffmann La Roche Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit
MX2016017288A (es) 2014-07-16 2017-06-27 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
MY198017A (en) * 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
EP4249066A3 (en) 2014-12-23 2023-11-22 Bristol-Myers Squibb Company Antibodies to tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN109071656B (zh) * 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
AU2018263857A1 (en) * 2017-05-01 2019-11-21 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
BR112020001499A2 (pt) * 2017-07-27 2020-09-08 Iteos Therapeutics Sa anticorpos anti-tigit
WO2019129221A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
CN113056285A (zh) * 2018-06-29 2021-06-29 璟尚生物制药公司 抗肿瘤免疫检查点调节剂拮抗剂

Also Published As

Publication number Publication date
PE20220505A1 (es) 2022-04-07
CN113939536A (zh) 2022-01-14
US20220227860A1 (en) 2022-07-21
SG11202112725XA (en) 2021-12-30
TWI760751B (zh) 2022-04-11
JP7241207B2 (ja) 2023-03-16
TW202110884A (zh) 2021-03-16
CA3139025A1 (en) 2020-12-03
CO2021015610A2 (es) 2021-11-30
BR112021021795A2 (pt) 2022-01-04
JP2023071889A (ja) 2023-05-23
WO2020242919A1 (en) 2020-12-03
CL2021003039A1 (es) 2022-08-05
CN113939536B (zh) 2024-05-14
MX2021014472A (es) 2022-01-06
DOP2021000241A (es) 2021-12-30
JOP20210314A1 (ar) 2023-01-30
IL287765A (en) 2022-01-01
EA202192796A1 (ru) 2022-03-03
CR20210573A (es) 2021-12-15
KR20220004120A (ko) 2022-01-11
MA56029A (fr) 2022-04-06
ECSP21085693A (es) 2021-12-30
AU2020283817A1 (en) 2021-11-25
JP2022533457A (ja) 2022-07-22
EP3976652A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
CL2021003039A1 (es) Moléculas de unión a tigit y pd-1/tigit
ECSP19013181A (es) Anticuerpos de anti-tim-3
CL2019001459A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1.
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
ECSP20007663A (es) Anticuerpos anti-cd137
CO2018002009A2 (es) Anticuerpos que se unen al ligando 1 de muerte celular programada 1 humana (pd-l1)
CY1122981T1 (el) Συνθεσεις για διαμορφωση της εκφρασης του c9orf72
WO2019126514A3 (en) Antibodies to lilrb2
MX2018001671A (es) Anticuerpos pd-1.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2017004650A (es) Composiciones topicas que contienen glicosaminoglicanos reticulados.
UY38472A (es) Moduladores de la expresión de foxp3
AR117079A1 (es) Moduladores de la expresión de foxp3
AR119639A1 (es) Moléculas de anticuerpo para cd73 y sus usos